We studied the effect of
quercetin (Q) on the proliferation of HT-29, WiDr, COLO 201, and LS-174T human
colon cancer cell lines. Q, between 10 nM and 10 microM, exerted a dose-dependent, reversible inhibition of cell proliferation. Cell-cycle analysis revealed that the growth-inhibitory effect of Q was due to a blocking action in the G0/G1 phase. Using a whole-cell assay with 17 beta-[3H]-
estradiol as tracer, we demonstrated that all these cell lines contain type-II
estrogen-binding sites (
type-II EBS). By using Q and other chemically related
flavonols (3,7-4'-trimethoxyquercetin, 3,7,3',4'-tetramethoxyquercetin,
kaempferol,
morin, and
rutin), we observed that the affinities of these compounds for
type-II EBS are correlated with their growth-inhibitory potential. Furthermore, the Q sensitivity of the
colon cancer cell lines was correlated with the number of
type-II EBS/cell. Then Q could regulate
colon cancer cell growth through a binding interaction with
type-II EBS. This mechanism could also be active in vivo as we have observed that cytosolic
type-II EBS are present in primary
colorectal cancers and that Q is effective in inhibiting the in vitro
bromodeoxyuridine incorporated by neoplastic cells in these
cancers.